OncoMatch/Clinical Trials/NCT06592924
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Is NCT06592924 recruiting? Yes, currently enrolling (Sep 2026). This Phase 3 trial studies multiple treatments for prostate cancer (adenocarcinoma).
Treatment: Abiraterone · Enzalutamide · Apalutamide · Darolutamide (BAY 1841788) · Docetaxel · ADT — This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better or worse than the usual approach for prostate cancer. The usual approach for patients who are not in a study is hormone treatment with Androgen Deprivation Therapy (ADT) and Androgen-Receptor Pathway Inhibitor (ARPI).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Endocrine / hormonal
Other
Cancer type
Prostate Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: androgen deprivation therapy — metastatic castration sensitive prostate cancer
Receipt of ADT for mCSPC for at least 6 months and no greater than 12 months (+/- 3 weeks) at time of enrollment.
Must have received: androgen receptor pathway inhibitor (abiraterone acetate, enzalutamide, apalutamide, darolutamide) — metastatic castration sensitive prostate cancer
Receipt of ARPI (e.g. abiraterone acetate, enzalutamide, apalutamide, or darolutamide) for at least 4 months (+/- 2 weeks) at time of enrollment
Cannot have received: taxane chemotherapy
Prior treatment with taxane chemotherapy
Cannot have received: other anti-cancer systemic therapy
Exception: other than ADT and ARPI
Concurrent treatment with other anti-cancer systemic therapy other than ADT and ARPI
Lab requirements
Blood counts
Adequate organ and marrow function measured within 28 days prior to enrollment.
Kidney function
Adequate organ and marrow function measured within 28 days prior to enrollment.
Liver function
Adequate organ and marrow function measured within 28 days prior to enrollment.
Adequate organ and marrow function measured within 28 days prior to enrollment.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Anchorage Associates in Radiation Medicine · Anchorage, Alaska
- Alaska Breast Care and Surgery LLC · Anchorage, Alaska
- Alaska Oncology and Hematology LLC · Anchorage, Alaska
- Alaska Women's Cancer Care · Anchorage, Alaska
- Katmai Oncology Group · Anchorage, Alaska
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06592924 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior taxane chemotherapy, other anti-cancer systemic therapy disqualifies patients from enrollment.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages